他克莫司和英夫利昔单抗治疗难治性类风湿关节炎的疗效分析  

Efficacy of Tacrolimus and Infliximab in the Treatment of Refractory Rheumatoid Arthritis

作　　者：方云 任颖玲 董章霞 陈慧慧 FANG Yun;REN Ying-ling;DONG Zhang-xia;CHEN Hui-hui(Department of Pharmacy,105th Hospital of PLA,Hefei 230001,China;Department of Rheumatology,105th Hospital of PLA,Hefei 230001,China)

机构地区：[1]解放军105医院药剂科,安徽合肥230001 [2]解放军105医院风湿免疫科,安徽合肥230001

出　　处：《解放军药学学报》2018年第6期568-570,共3页Pharmaceutical Journal of Chinese People's Liberation Army

基　　金：2015年度南京军区医学科技创新课题项目;No.15MS050

摘　　要：目的分析他克莫司和英夫利昔单抗对难治性类风湿关节炎的临床疗效,并评估其安全性。方法收集2016年4月至2018年2月在解放军105医院风湿免疫科治疗的难治性类风湿关节炎患者84例。使用数字表法随机分为他克莫司组和英夫利昔单抗组,每组42例,比较两组临床疗效和不良反应发生率。结果治疗后英夫利昔单抗组晨间僵时间、关节疼痛数、关节肿胀数、DAS28评分、ESR均显著低于他克莫司组(P <0.05)。英夫利昔单抗组总缓解率为73.8%(31/42),显著高于他克莫司组的61.9%(26/42)(P <0.05)。他克莫司组临床不良反应发生率为16.7%(7/42),显著低于英夫利昔单抗组的28.6%(12/42)(P <0.05)。结论他克莫司治疗难治性类风湿关节炎临床缓解率低于英夫利昔单抗组治疗,但是他克莫司组的临床不良反应发生率显著低于英夫利昔单抗组。Objective To analyze the clinical efficacy and safety of tacrolimus and infliximab combined with methotrexate in the treatment of refractory rheumatoid arthritis.Methods Eighty-four patients of refractory rheumatoid arthritis were enrolled in this study.The clinical effects and the incidence of adverse reactions were compared.Results After treatment,the duration of morning stiffness,incidence of pain of joints,incidence of swelling of joints,DAS28 score,and ESR were shorter or lower in infliximab group than that in tacrolimus group(P <0.05).The total remission rate in infliximab group was 73.8%(31/42),which was significantly higher than 61.9%(26/42)in tacrolimus group(P <0.05).The incidence of adverse reactions in tacrolimus group was 16.7%(7/42),which was significantly lower than 28.6%(12/42)in infliximab group(P <0.05).Conclusion The clinical remission rate of tacrolimus in the treatment of refractory rheumatoid arthritis is lower than that of infliximab,but the incidence of adverse reactions in the tacrolimus group is significantly lower than that in the infliximab group.

关 键 词：难治性类风湿关节炎 他克莫司 英夫利昔单抗 

分 类 号：R969.3[医药卫生—药理学]